Reliv International Reports Third-Quarter Financial Results

Reliv International Reports Third-Quarter Financial Results

CHESTERFIELD, Mo., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Reliv International, Inc.
(Nasdaq:RELV), a maker of nutritional supplements that promote optimal health,
today reported its financial results for the third quarter of 2013.

Net sales for the quarter were $16.5 million, an 8.3 percent increase from the
third quarter last year. Net U.S. sales totaled $13.2 million, an increase of
$1.1 million, or 9.0 percent, compared to third-quarter 2012 net sales. Net
sales outside of the United States rose 5.4 percent in the third quarter of
2013 compared to the prior-year quarter, led by the European market where net
sales increased by 21.3 percent.

Income from operations for the third quarter of 2013 increased to $402,000
compared to a loss of $32,000 in the same quarter of 2012 due to the increase
in net sales in the United States. Net income for the third quarter of 2012
included a one-time after-tax gain of approximately $247,000 resulting from a
discounted balance due on a purchase agreement entered into in a previous
year. As a result, net income for the third quarter of 2012 was $287,000 or
$0.02 per diluted share, compared to net income for the third quarter of 2013
of $293,000 or $0.02 per diluted share.

Third quarter 2013 net sales grew in the United States as Reliv continues to
focus on its LunaRich® product line. The LunaRich product line contains
elevated levels of lunasin, a naturally occurring soy peptide that works at
the epigenetic level in cells to promote optimal health. Reliv acquired the
exclusive rights to certain intellectual property related to lunasin and its
production from Soy Labs, LLC in July 2013.

"The word is getting out about lunasin as new studies emerge," said Robert L.
Montgomery, Chairman and CEO of Reliv. "Reliv's LunaRich® products deliver
more bioactive lunasin than any other product available today, and for the
first time we control an ingredient in its entirety, from the extraction
process to the patented mechanisms of action within the body." U.S.
third-quarter net sales were led by the flagship products in the LunaRich
line, Reliv Now® and LunaRich X™, which made up 18.1 and 13.2 percent of U.S.
sales, respectively.

Also, sales in the United States were boosted by the impact of its Ignition
Master Affiliate qualification promotion. The number of new Master Affiliates,
the level at which distributors are eligible to earn generation royalties,
increased to 694 during the third quarter of 2013 compared to 284 during same
period in 2012, an increase of 144%. "People are seeing health results with
Reliv's LunaRich products and entrepreneurs are seeing a potentially lucrative
business opportunity in distributing nutritional products containing an
exclusive ingredient," said Montgomery. "The lunasin technology acquisition
coupled with a promotion that encourages distributor advancement to the Master
Affiliate level has created an ideal environment to launch a Reliv
distributorship."

Montgomery added: "The epigenetic science behind lunasin gives Reliv a
competitive advantage in the supplement industry. Today's health care concerns
are creating high demand for proactive approaches to wellness. Nutritional
epigenetics and the idea that you can help direct your DNA naturally through
nutrition holds the potential for mass appeal. We believe no other products
are positioned to fill this market need like Reliv's LunaRich line."

Growth in Europe continued with net sales of $1.7 million in the third quarter
of 2013 compared to $1.4 million in the prior-year third quarter. "Europe
remains Reliv's strongest international market and we expect growth to
continue," Montgomery said.

Worldwide net sales for the first nine months of 2013 were $50.8 million,
representing a 1.9 percent decrease from the same period in 2012. In the
United States, net sales declined 1.7 percent compared with the first nine
months of the prior year. Net sales outside of the United States decreased by
2.7 percent in the first nine months of 2013 compared with the first nine
months last year.

Reliv reported net income of $274,000, or $0.02 per diluted share in the first
nine months of 2013, compared to $922,000 or $0.07 per diluted share in the
same period of 2012.

Reliv's total distributor count was 51,920 as of September 30, 2013 – a
decrease of 11.4 percent from the same date in 2012 – of which 6,670 are
Master Affiliate level and above. The number of Master Affiliates decreased by
0.6 percent compared to the year ago total.

Net cash generated from operating activities in the first nine months of 2013
totaled $1.3 million, representing an increase of $243,000 over the first nine
months of 2012. Reliv had cash and cash equivalents of $5.7 million as of
September 30, 2013, an increase of $843,000 from the same date last year.

About Reliv International, Inc.

Reliv International, based in Chesterfield, MO, produces nutritional
supplements that promote optimal nutrition along with premium skincare
products. Reliv supplements address essential nutrition, weight loss, athletic
performance, digestive health, women's health, anti-aging and healthy energy.
Reliv is the exclusive provider of LunaRich® products, which optimize levels
of lunasin, the peptide behind many of soy's health benefits. The company
sells its products through an international network marketing system of
independent distributors in 16 countries. Learn more about Reliv at
www.reliv.com, or on Facebook, Twitter or YouTube.

Statements made in this news release that are not historical facts are
"forward-looking" statements (as defined in the Private Securities Litigation
Reform Act of 1995) that involve risks and uncertainties and are subject to
change at any time. These forward-looking statements may include, but are not
limited to, statements containing words such as "may," "should," "could,"
"would," "expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" or similar expressions. Factors that could cause
actual results to differ are identified in the public filings made by Reliv
with the Securities and Exchange Commission. More information on factors that
could affect Reliv's business and financial results are included in its public
filings made with the Securities and Exchange Commission, including its Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are
available on the Company's web site, www.reliv.com.

                       – FINANCIAL HIGHLIGHTS FOLLOW –

Reliv International, Inc.                                   
and Subsidiaries
ADD TWO                                                     
                                                           
Condensed Consolidated                                      
Balance Sheets
                         September 30 December 31            
                         2013         2012                   
                         (Unaudited)                        
Assets                                                      
Current Assets:                                             
Cash and cash equivalents $5,744,193   $5,801,042             
Accounts receivable, less
allowances of $23,000 in  253,864      247,087                
2013 and $35,700 in 2012
Accounts and note due
from employees and        137,408      109,346                
distributors
Inventories               5,080,058    5,262,916              
Other current assets      1,356,381    1,070,301              
                                                           
Total current assets      12,571,904   12,490,692             
                                                           
Other assets              4,432,385    4,212,442              
Intangible assets, net    3,263,436    1,443,635              
Net property, plant and   6,880,018    7,111,772              
equipment
                                                           
Total Assets              $27,147,743  $25,258,541            
                                                           
Liabilities and                                             
Stockholders' Equity
                                                           
Total current liabilities $7,817,234   $6,614,631             
Long-term debt, less      2,747,455    2,401,312              
current maturities
Other non-current         987,362      660,728                
liabilities
Stockholders' equity      15,595,692   15,581,870             
                                                           
Total Liabilities and     $27,147,743  $25,258,541            
Stockholders' Equity
                                                           
                                                           
Consolidated Statements                                                   
of Operations
                         Three months ended       Nine months ended
                          September 30             September 30
                         2013         2012        2013        2012
                         (Unaudited)  (Unaudited) (Unaudited) (Unaudited)
Product sales             $15,241,597  $13,571,674 $46,296,517 $46,081,154
Handling & freight income 1,297,867    1,704,862   4,525,618   5,719,730
                                                           
Net Sales                 16,539,464   15,276,536  50,822,135  51,800,884
                                                           
Costs and expenses:                                         
Cost of products sold     3,529,027    3,052,687   10,490,825  10,174,128
Distributor royalties and 5,974,652    5,737,908   18,595,100  19,512,681
commissions
Selling, general and      6,633,771    6,517,747   21,121,858  21,013,651
administrative
                                                           
Total Costs and Expenses  16,137,450   15,308,342  50,207,783  50,700,460
                                                           
Income (loss) from        402,014      (31,806)    614,352     1,100,424
operations
                                                           
Other income (expense):                                     
Interest income           37,240       36,681      113,072     86,858
Interest expense          (22,187)     (20,124)    (58,182)    (82,338)
Other income (expense)    28,637       437,745     (62,482)    376,513
                                                           
Income before income      445,704      422,496     606,760     1,481,457
taxes
Provision for income      153,000      135,000     333,000     559,000
taxes
                                                           
Net Income                $292,704     $287,496    $273,760    $922,457
                                                           
                                                           
Earnings per common share $0.02        $0.02       $0.02       $0.07
- Basic
Weighted average shares   12,616,000   12,480,000  12,617,000  12,499,000
                                                           
Earnings per common share $0.02        $0.02       $0.02       $0.07
- Diluted
Weighted average shares   12,842,000   12,636,000  12,785,000  12,657,000
                                                           
Cash dividends declared   $--        $--       $0.02       $0.02
per common share


Reliv International, Inc. and Subsidiaries
ADD THREE
                                                                     
Net sales by                                                             
Market
(in                                                                   
thousands)
             Three months ended September 30,                Change From
                                                              Prior Year
             2013                    2012                    
             Amount       % of Net   Amount       % of Net   Amount       %
                           Sales                   Sales
                                                                     
United States $13,163    79.6%      $12,073    79.0%      $1,090     9.0%
Australia/New 429         2.6%       462         3.0%       (33)        -7.1%
Zealand
Canada        384         2.3%       381         2.5%       3           0.8%
Mexico        225         1.4%       274         1.8%       (49)        -17.9%
Europe        1,685       10.2%      1,389       9.1%       296         21.3%
Asia          653         3.9%       698         4.6%       (45)        -6.4%
                                                                     
Consolidated  $16,539    100.0%     $15,277    100.0%     $1,262     8.3%
total
                                                                     
                                                                     
Net sales by                                                          
Market
(in                                                                   
thousands)
             Nine months ended September 30,                 Change From
                                                              Prior Year
             2013                    2012                    
             Amount       % of Net   Amount       % of Net   Amount       %
                           Sales                   Sales
                                                                     
United States $40,101    78.9%      $40,786    78.7%      $(685)     -1.7%
Australia/New 1,402       2.8%       1,482       2.9%       (80)        -5.4%
Zealand
Canada        1,310       2.6%       1,370       2.7%       (60)        -4.4%
Mexico        759         1.5%       832         1.6%       (73)        -8.8%
Europe        5,664       11.1%      4,724       9.1%       940         19.9%
Asia          1,586       3.1%       2,607       5.0%       (1,021)     -39.2%
                                                                     
Consolidated  $50,822    100.0%     $51,801    100.0%     $(979)     -1.9%
total
                                                                     
The following table sets forth, as of September 30, 2013 and 2012, the number of our
active distributors and Master Affiliates and above.We define an active distributor
as one that enrolls as a distributor or renews its distributorship during the prior
twelve months.Master Affiliates and above are distributors that have attained the
highest level of discount and are eligible for royalties generated by Master
Affiliates and above in their downline organization.Beginning with the September 30,
2013 data, the active distributor count for Europe includes our preferred customers
in France.This program began in mid-2013 and the Europe active distributor count as
of 9/30/13 includes 1,040 preferred customers.
                                                                     
Active Distributors and Master Affiliates and above by Market             
                                                                     
             As of 9/30/2013         As of 9/30/2012         Change in %
              Total       Master     Total       Master     Total       Master
             Active       Affiliates Active       Affiliates Active       Affiliates
              Distributors and Above  Distributors and Above  Distributors and
                                                                           Above

                                                                     
United States 38,670       4,830      41,300       4,990      -6.4%        -3.2%
Australia/New 1,470        200        1,910        150        -23.0%       33.3%
Zealand
Canada        1,270        220        1,270        210        0.0%         4.8%
Mexico        1,080        150        1,810        150        -40.3%       0.0%
Europe        5,800        820        6,440        650        -9.9%        26.2%
Asia          3,630        450        5,840        560        -37.8%       -19.6%
                                                                     
Consolidated  51,920       6,670      58,570       6,710      -11.4%       -0.6%
total

CONTACT: For more information, contact:

         Steve Albright
         Chief Financial Officer
         (636) 733-1305
 
Press spacebar to pause and continue. Press esc to stop.